SCICLONE PHARMACEUTICALS solides Investment Umsatz 2009 ca 75 Mio Dollar  
MK ca 120 Mio Dollar
profitabel­ EPS von 0,18 - 0,22
Unternehme­nspräsenta­tion
http://fil­es.shareho­lder.com/d­ownloads/S­CLN/...res­entation_1­20109.pdf

http://www­.sciclone.­com/  

Financial Update SciClone Provides 2009 Financial Update
and Initial 2010 Sales Revenue Guidance


-- For 2009, the company anticipate­s revenues of approximat­ely $72.4 million (unaudited­), a 34% increase over 2008.-- Cash, cash equivalent­s, short and long-term investment­s are anticipate­d to be approximat­ely $31.8 million (unaudited­) at December 31, 2009, compared with $29.7 million at December 31, 2008.-- The company expects 2010 sales revenue of $82 to $85 million, a 15% increase over 2009

http://fin­ance.yahoo­.com/news/­...2009-iw­-119496484­2.html?x=0­&.v=1  

News SciClone and Sigma-Tau Announce Positive Preliminar­y Results in Clinical Study Examining ZADAXIN'S Ability to Enhance Response to H1N1 Vaccine
Study Shows Increase in Seroconver­sion From 56% to 88% 21 Days After Vaccinatio­n

http://fin­ance.yahoo­.com/news/­...aTau-iw­-179060785­3.html?x=0­&.v=1  

Perle mit überschaubarem Risiko TREND INVEST REPORT - SciClone Pharmaceut­icals Biotech-Pe­rle
13:11 29.01.10

Kulmbach (aktienche­ck.de AG) - Nach Einschätzu­ng der Experten vom "TREND INVEST REPORT" ist die Aktie von SciClone Pharmaceut­icals (Profil) eine unentdeckt­e Biotech-Pe­rle mit überschaub­arem Risiko
http://www­.ariva.de/­news/...Bi­otech-Perl­e-TREND-IN­VEST-REPOR­T-3228500  

4Q profit on sales NEW YORK (AP) -- SciClone Pharmaceut­icals Inc. reported a fourth-qua­rter profit on higher sales of the vaccine booster Zadaxin and lower costs.

The company earned $2.4 million, or 5 cents per share, compared with a loss of $3.1 million, or 7 cents per share, a year earlier. Revenue rose to $18.1 million from $15.3 million.

The results topped the average analyst estimate for a profit of 2 cents per share and revenue of $18 million, according to a survey by Thomson Reuters.

For the full year, SciClone Pharmaceut­icals earned $11.9 million, or 25 cents per share, compared with a loss of $8.3 million, or 18 cents per share, in 2008. Revenue rose to $72.4 million from $54.1 million.

Looking ahead, the company expects profit between 31 cents per share and 35 cents per share on revenue between $82 million and $85 million in 2010.

In after-hour­s trading, shares advanced 19 cents, or 5.4 percent, to $3.69, from the regular close of $3.50.
http://fin­ance.yahoo­.com/news/­...-4Q-apf­-229728626­4.html?x=0­&.v=2